Nature’s Sunshine backs FY25 revenue view $445M-$470M, consensus $459.06M

Backs FY25 adjusted EBITDA view $38M-$44M. The company said, “We’re particularly pleased with the exceptional growth we’re seeing in Asia and Europe where markets like Taiwan, Japan and Central Europe continue to deliver strong double-digit growth. We’re also pleased to see early signs of stabilization in North America and continued improvements to gross margin. Despite the tremendous amount of uncertainty in the market, we remain confident in the underlying health of our business, and our performance reflects the power of our global growth strategies. In addition, our Board has authorized the repurchase of up to $25 million in common stock, supplementing the $8.3 million remaining under the current authorization, as we continue to make disciplined investments with the highest potential return for our shareholders.”